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licenses/by/4.0/).Abstract Background: AZD8931 has equipotent activity against epidermal growth factor re-
ceptor, erbB2, and erbB3. Primary objectives were to determine the recommended phase II
dose (RP2D) of AZD8931 þ chemotherapy, and subsequently assess safety/preliminary clin-
ical activity in patients with operable oesophagogastric cancer (OGC).
Method s : AZD8931 ( 2 0 mg , 4 0 mg o r 60 mg bd ) wa s g i v e n w i t h Xe l o x
(oxaliplatin þ capecitabine) for eight 21-day cycles, continuously or with intermittent schedule
(4 days on/3 off every week; 14 days on/7 off, per cycle) in a rolling-six design. Subsequently,
patients with OGC were randomised 2:1 to AZD8931 þ Xelox at RP2D or Xelox only for twocer Research Centre, University of Leicester, Osborne Building, Leicester Royal Infirmary, Leicester, LE1
Thomas).
ed by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
A. Thomas et al. / European Journal of Cancer 124 (2020) 131e141132cycles, followed by radical oesophagogastric surgery. Secondary outcomes were safety, com-
plete resection (R0) rate, six-month progression-free survival (PFS) and overall survival.
Results: During escalation, four dose-limiting toxicities were observed among 24 patients: skin
rash (1) and failure to deliver 100% of Xelox because of treatment-associated grade III-IV
adverse events (AEs) (3: diarrhoea and vomiting; vomiting; fatigue). Serious adverse events
(SAE) occurred in 15 of 24 (63%) patients. RP2D was 20-mg bd with the 4/3 schedule. In
the expansion phase, 2 of 20 (10%) patients in the Xelox þ AZD8931 group and 5/10
(50%) patients in the Xelox group had grade IIIeIV AEs. Six-month PFS was 85% (90%
CI: 66%e94%) in Xelox þ AZD8931 and 100% in Xelox alone. Seven deaths (35%) occurred
with Xelox þ AZD8931 and one (10%) with Xelox. R0 rate was 45% (9/20) with
Xelox þ AZD8931 and 90% (9/10) with Xelox-alone (P Z 0.024).
Conclusion: Xelox þ AZD8931 (20 mg bd 4/3 days) has an acceptable safety profile adminis-
tered as neoadjuvant therapy in operable patients with OGC. (Trial registration: EudraCT
2011-003169-13, ISRCTN-68093791).
ª 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
In the UK, gastric and oesophageal cancers account for
approximately 16,000 cases per annum with mortality
approaching 13,000 cases per annum [1]. In the western
world, oesophageal adenocarcinoma incidence rates
have increased markedly over the last 30 years [2] with
the majority of patients presenting with advanced dis-
ease [3]. The UK national oesophagogastric cancer
(OGC) audit (2018) determined that only 38.6% of pa-
tients were treated with curative intent, with a 5-year
overall survival (OS) of 15% for oesophageal and 19%
for gastric cancers [4]. There is, therefore, an urgent need
to develop more effective therapies.
Patients with operable OGC may be treated with
neoadjuvant chemotherapy [5], perioperative chemo-
therapy [6e8], or preoperative chemoradiotherapy [9].
The choice of therapy depends on the location of the
tumour, the histology (squamous versus adenocarci-
noma), the patient’s performance status, and their co-
morbidity. Several other strategies, including treatment
intensification [10] and anti-angiogenic therapies [11],
have failed to demonstrate additional benefit in operable
patients. Trastuzumab has demonstrated activity in
patients with advanced human epidermal growth factor
receptor-2 (EGFR) (HER2/erbB2) positive OGC
[12,13], and results from neoadjuvant studies using this
in addition to chemotherapy are awaited [14,15].
Whilst HER2 is an established target in OGC, further
molecular subclassifications include overexpression of
EGFR (HER1/erbB1) and heterodimeric activation of
HER2 via erbB3 (HER3) [16,17], advocating extension
of therapeutic targeting encompassing the wider EGFR
family. AZD8931 is a novel small-molecule inhibitor,
which has equipotent activity against signalling by
EGFR, erbB2, and erbB3. In preclinical models,
AZD8931 has greater anti-cancer activity than other
EGFR inhibitors, such as gefitinib and lapatinib, whichhave narrower spectrums of erbB receptor inhibition
[18]. AZD8931 combined with chemotherapy may,
therefore, have activity in a wider group of patients with
OGC (and other solid tumour) than for those just
exhibiting highly HER2 amplified disease.
The Dual Erb B Inhibition in Oesophago-gastric
Cancer (DEBIOC) study sought to establish the
maximum tolerated dose (MTD) of AZD8931 in com-
bination with oxaliplatin and capecitabine (Xelox) in
patients with OGC (dose escalation phase). After
establishment of the recommended phase II dose
(RP2D), the dose expansion phase aimed to give pre-
liminary efficacy assessments and further investigate the
safety and tolerability of AZD8931 in combination with
Xelox.
2. Materials and methods
The DEBIOC study was conducted in accordance with
the International Conference of Harmonisation of Good
Clinical Practice and the Declaration of Helsinki.
Ethical approval was provided by a research ethics
committee (12/SC/0090).
2.1. Patients
For dose escalation, eligible participants were chemo-
naive with inoperable metastatic OGC (measurable by
RECIST 1.1), aged 18 years, had World Health
Organisation performance status of 0 or 1 and adequate
haematological, renal, hepatic, respiratory, and cardiac
function. For dose expansion, eligible patients had his-
tologically confirmed operable adenocarcinoma of the
oesophagus or gastrooesophageal junction, including
Siewert type I and II gastrooesophageal junction can-
cers, and were deemed suitable for neoadjuvant
chemotherapy. Patients who had received prior chemo-
therapy for OGC were excluded. The full inclusion and
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Appendix A. All participants provided written
informed consent.
2.2. Study design and treatment
For dose escalation, a rolling-six design [19] was used,
with three oral AZD8931 dose levels: 20 mg bd, 40 mg
bd, and 60 mg bd. Two intermittent schedules of
AZD8931 were investigated once recruitment to the
20 mg bd group was complete: 14 days on/7 days off
(schedule 1) and 4 days on/3 days off every week in a
cycle (schedule 2). Patients would receive oral AZD8931
monotherapy twice daily for three days, then together
with Xelox chemotherapy from day 4 for eight 21-day
cycles (Xelox: oxaliplatin at 130 mg/m2 IV over 2 h on
day one of every cycle; capecitabine 1250 mg/m2 bd for
cycle duration). AZD8931 could continue after cessation
of Xelox providing there was no evidence of tumour
progression and treatment was tolerated.
The dose expansion phase was an open-label study,
with patients randomised 2:1 to receive either
Xelox þ AZD8931 at AZD8931 RP2D for two 21-day
cycles, or Xelox alone as neoadjuvant treatment. Pa-
tients without disease progression (as per RECIST 1.1)
would undergo radical oesophagogastric surgical resec-
tion with extended lymph node dissection 4-6 weeks
after completing neoadjuvant chemotherapy. Those who
received AZD8931 in the expansion phase could
commence maintenance AZD8931 at the same dose,
6e12 weeks after successful surgical resection (complete
[R0]/marginal [R1]) for up to 12 months (if no evidence
of recurrent disease). Safety follow-up was scheduled for
four weeks after AZD8931 treatment ended. Tumour
response assessment was performed via CT scan at 43
days from commencing neoadjuvant treatment to
determine eligibility for surgery and at six months after
surgery for analysis of outcomes.
2.3. Sample size
The maximum number of participants for dose escala-
tion was 42: six patients taking one of three dose levels
for two intermittent schedules, plus up to six patients
recruited before implementation of the intermittent
schedules.
Sample size for the expansion phase was based on
observing outcomes that would render the AZD8931
regimen worthy of further investigation: with 20 patients
receiving AZD8931, 78% progression-free survival
(PFS) at 6 months from surgery corresponds to a lower
one-sided 95% confidence limit for true 6-month PFS of
54%. In addition, an 80% R0 resection rate among 20
patients corresponds to a lower one-sided 80% confi-
dence limit of 64%. Patients were randomised 2:1 with
the majority receiving the treatment combination. One
reason for this was to ensure sufficient numbers toevaluate feasibility of maintenance treatment, as drop-
out after surgery was envisaged. The Xelox alone
(reference) arm size was 10, giving a total of 30 patients
to be randomised in the expansion phase.
2.4. Statistical analysis
The primary objective of the study was to determine
the MTD of AZD8931 in combination with Xelox,
defined as the highest dose level at which fewer than
2 of 6 patients experienced a dose limiting toxicity
(DLT). DLTs were based on clinical and laboratory
toxicity assessments (defined by National Cancer
Institute-Common Toxicity Criteria, version 4.0, with
the full definition provided in Supplementary
Appendix B). Patients were evaluable for dose esca-
lation analysis if they completed cycle 1 of AZD8931
treatment or withdrew from cycle 1 because of a
DLT.
Secondary outcomes (dose expansion phase only)
were PFS, PFS at 6 months, R0 rate at surgery, OS,
OS at 12 months and safety. PFS was defined as time
(days) from randomisation to progression (determined
by RECIST 1.1) or death from any cause. Patients
without disease progression and alive at the end of the
study were censored at the date they were last known
to be alive and progression-free. R0 rate was defined
as the proportion of patients achieving a complete
surgical resection divided by the total number of pa-
tients randomised in the respective arm. OS was
defined as the time (days) from randomisation to
death (any cause). Patients who were alive at the end
of the study were censored at the date they were last
known to be alive. Adverse events (AEs) were defined
using the Common Terminology Criteria for Adverse
Events, v4.03, and collected from the first day of
treatment up to 30 days after ending treatment. Safety
analyses were performed on an as-treated basis in
both phases of the study. There were two safety
populations in the expansion phase: patients who
received at least one dose during the neoadjuvant
period and patients who received at least one dose of
maintenance AZD8931 postoperatively. Escalation
phase safety data were summarised descriptively for
each dose cohort separately and overall, with the
number and percentage of patients experiencing each
type of AE reported. Expansion phase safety data
were summarised in accordance with the type and
grade of AE, with number and percentage of patients
experiencing the AE reported. Efficacy analyses
(expansion phase only) were performed on an
intention-to-treat basis. In the expansion phase, me-
dian follow-up time was calculated using the reverse
Kaplan-Meier method [20]. The six-month PFS (90%
CI), 12-month OS (90% CI) and 24-month OS (90%
CI) estimates were taken from Kaplan-Meier survival
curves. R0 rate was compared between groups using
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Stata, version 15.1 (StataCorp, College Station, TX,
USA) and R, version 3.4.2. A (two-sided) 10% sig-
nificance level was used.
3. Results
3.1. Patients
Twenty-four patients were recruited to the escalation
phase between June 2012 and October 2014 in three
ECMC UK centres (Oxford, Leicester and Belfast).
Thirty patients were randomised to the expansion phase
between March 2015 and May 2016 in five ECMC UK
centres (Oxford, Leicester, Belfast, Bristol and Leeds)
and follow-up ended in November 2017. Consolidated
Standards of Reporting Trials (CONSORT) diagrams
are shown for escalation and expansion phases (Fig. 1
and Fig. 2, respectively). Baseline demographics for
escalation and expansion phases are summarised in
Tables 1 and 2, respectively. The number of patients by
HER2 status in addition to sample discordance between
those collected at baseline (biopsy) and at surgery is
described in Table 3.
3.2. Treatment compliance
In the escalation phase, all patients received AZD8931
monotherapy in the 3-day run in period without missed20mg BD Continuous N=6
Evaluable for dose escalation 
analysis (n=6) 
- DLT  (n=1) 
- No DLT  (n=5) 
Evaluable for safety analysis 
(n=6) 
Assessed for eligibi
N=66
Eligible and recr
20mg BD (14 on, 7 off) N=7
Evaluable for dose escalation 
analysis (n=6) 
- DLT   (n=1) 
- No DLT  (n=5) 
Not evaluable for dose escalation 
analysis (n=1) 
- Cycle 1 not completed (n=1) 
Evaluable for safety analysis 
(n=7) 
Escalate Escalat
Fig. 1. CONSORT diagram showing patient flow for the phase I dos
oxaliplatin and capecitabine (Xelox) chemotherapy in patients with oeor reduced doses. In cycle 1 of AZD combined with
Xelox, five patients missed AZD8931 doses because of
AEs (fatigue, diarrhoea, poor oral, vomiting and coro-
nary spasm), by own choice, or in error. Three patients
did not complete cycle 1 of Xelox: one withdrew con-
sent, one because of experiencing a rash, and one
because of experiencing a coronary spasm. Over all cy-
cles, patients stopped AZD8931 because of toxicity
(n Z 7, 29%), disease progression (n Z 16, 67%) or
consent withdrawal (n Z 1, 4%).
In the expansion phase, 14 of 20 patients (70%)
completed two cycles of neoadjuvant AZD8931
treatment in the Xelox þ AZD8931 group. Three
(15%) did not complete two cycles: one due to an AE
(out of range liver function test) and two due to a
serious adverse event (SAE) (diarrhoea). AZD8931
diary cards for the other three patients were un-
available, so it could not be confirmed that they
completed the two cycles of AZD8931. Seventeen
patients (85%) completed two cycles of neoadjuvant
Xelox treatment; all patients received their allocated
oxaliplatin, but two patients did not complete cape-
citabine treatment due to a SAE (diarrhoea). The
diary card for one patient was unavailable, so it
could not be confirmed whether the two cycles of
capecitabine were completed.
Of the 10 patients in the Xelox-alone group, six (60%)
completed two cycles of neoadjuvant Xelox. Two pa-
tients (20%) did not complete two cycles because of aExcluded N=42
Not meeting inclusion criteria  (n=28) 
Refused to participate  (n=13) 
Other reasons    (n=1) 
lity and consent  
 
uited N=24 
20mg BD (4 on, 3 off) N=7
Evaluable for dose escalation 
analysis (n=6) 
- DLT   (n=0) 
- No DLT  (n=6) 
Not evaluable for dose escalation 
analysis (n=1) 
- Cycle 1 not completed (n=1) 
Evaluable for safety analysis 
(n=7) 
40mg BD (4 on, 3 off) N=4
Evaluable for dose escalation 
analysis (n=4) 
- DLT   (n=2) 
- No DLT  (n=2) 
Evaluable for safety analysis 
(n=4) 
e Escalate
e escalating study component for AZD8931 in combination with
sophago-gastric adenocarcinoma. BD, bi-daily.
Fig. 2. CONSORT diagram showing patient flow for the randomised phase II dose expansion study component for AZD8931 in com-
bination with oxaliplatin and capecitabine (Xelox) chemotherapy in patients with oesophagogastric adenocarcinoma vs Xelox alone. ITT,
intention to treat.
A. Thomas et al. / European Journal of Cancer 124 (2020) 131e141 135SAE (diarrhoea) and AE (atrial fibrillation). Diary cards
for the remaining two patients were unavailable, so it
could not be confirmed whether they completed the two
cycles of AZD8931.
In the XeloxþAZD8931 group, 17 of 20 patients had
surgery, compared with 10 of 10 patients in the Xelox-
alone group. Of the 17 patients in the Xelox þ AZD8931
group who had surgery, 11 continued to AZD8931
maintenance, with six completing 12 months of treat-
ment. Three patients stopped treatment because of dis-
ease progression, one as per the decision of the treating
clinician and one in error after taking approximately 11
months of maintenance AZ8931.3.3. Adverse events
During dose escalation, there were 428 grade IeIV AEs:
77 occurred during cycle 1 and 351 after cycle 1. All but
one patient experienced at least four AEs during theescalation phase. There were 62 grade IIIeIV AEs: six
during cycle 1 and 56 after cycle 1. AEs at grade III were
experienced by 20 (83%) patients, with the most com-
mon grade IIIeIV AEs being diarrhoea (n Z 7, 29%)
and vomiting (nZ 4, 17%) (Table 4). Thirty-three SAEs
in fifteen (63%) patients were reported during dose
escalation: four during cycle 1 and 29 after cycle 1. Of
these SAEs, 39% (13/33) were deemed related to
AZD8931. Common SAEs were diarrhoea (nZ 9, 38%)
and vomiting (n Z 4, 17%). There were six suspected
unexpected serious adverse reactions (SUSARs) among
four patients, none of which were deemed definitely
related to AZD8931: three (13%) patients experienced
vomiting (one at grade II; two at grade III; all SAEs
were possibly related to AZD8931) and two (8%)
experienced diarrhoea (all at grade III and possibly or
probably related to AZD8931). Note: one patient had
both diarrhoea (on two separate occasions) and
vomiting.
Table 1
Baseline demographics for patients in the dose escalation phase (n Z 24).
Variable 20 mg BD
Cont.
(n Z 6)
20 mg BD 14on
7 off
(n Z 7)
20 mg BD 4on
3 off
(n Z 7)
40 mg BD 4on
3 off
(n Z 4)
Total
(n Z 24)
Age, in years, median (range) 63 (35e72) 74 (52e78) 60 (43e69) 54 (39e69) 62 (35e78)
Gender male, n (%) 5 (83%) 6 (86%) 4 (57%) 3 (75%) 18 (75%)
WHO PS 0, n (%) 5 (83%) 5 (71%) 6 (86%) 3 (75%) 19 (79%)
WHO PS 1, n (%) 1 (17%) 2 (29%) 1 (14%) 1 (25%) 5 (21%)
HER2 status positive, n (%) 3 (50%) 2 (29%) 2 (29%) 1 (25%) 8 (33%)
HER2 status negative, n (%) 3 (50%) 5 (71%) 4 (57%) 3 (75%) 15 (63%)
HER2 status unknown, n (%) 0 0 1 (14%) 0 1 (4%)
Locally advanced disease, n (%) 0 0 2 (29%) 0 2 (8%)
Metastatic disease, n (%) 6 (100%) 7 (100%) 5 (71%) 4 (100%) 22 (92%)
Prior radiotherapy, n (%) 0 1 (14%) 0 0 1 (4%)
BD, bi-daily; WHO PS, World Health Organisation performance status; HER2, human epidermal growth factor receptor-2.
Table 2
Baseline demographics for the expansion phase by treatment group (n Z 30).
Variable AZD893 þ XELOX (n Z 20) XELOX (n Z 10) Total (n Z 30)
Age, years, median (range) 63 (50e78) 66 (25e75) 64 (25e78)
Gender male, n (%) 17 (85%) 10 (100%) 27 (90%)
WHO PS 0, n (%) 17 (85%) 7 (70%) 24 (80%)
WHO PS 1, n (%) 3 (15%) 3 (30%) 6 (20%)
HER2 status, positive, n (%) 1 (5%) 0 1 (3%)
HER2 status, negative, n (%) 15 (75%) 8 (80%) 23 (77%)
HER2 status, unknowna, n (%) 4 (20%) 2 (20%) 6 (20%)
EGFR status, positive, n (%) 6 (30%) 4 (40%) 10 (33%)
EGFR status, negative, n (%) 10 (50%) 4 (40%) 14 (47%)
EGFR status, unknowna, n (%) 4 (20%) 2 (20%) 6 (20%)
Siewert type I, n (%) 4 (20%) 1 (10%) 5 (17%)
Siewert type II, n (%) 7 (35%) 2 (20%) 9 (30%)
Siewert type Oesophagus, n (%) 9 (45%) 7 (70%) 16 (53%)
EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor-2; WHO PS, World Health Organisation performance
status.
a Status unknown at biopsy because of block being unavailable (5); did not consent for use (1).
Table 3
Number of patients by HER2 status. Discordance in HER2 status is
shown between diagnostic biopsy and resection specimens.
Diagnostic
Biopsy
Resection
specimens
Xelox þ AZD8931
(n Z 20)
Xelox
(n Z 10)
HER2
status
Positive Negative Unknown Positive Negative Unknown
Positive 0 1 0 0 0 0
Negative 2 9 4 0 6 2
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phase, 144 AEs were reported in total. In the Xelox-
alone group, 90% (9/10) of patients had an AE,
compared with 80% (16/20) in the Xelox þ AZD8931
group. The most common AEs were diarrhoea (9/20,
45% Xelox þ AZD8931; 4/10, 40% Xelox alone), nausea
(8/20, 40% Xelox þ AZD8931; 2/10, 20% Xelox alone)
and fatigue (7/20, 35% Xelox þ AZD8931; 5/10, 50%
Xelox alone). AEs by system organ are reported in
Fig. 3. Grade IIIeIV AEs were reported in 2 of 20 (10%)
patients in the Xelox þ AZD8931 group and 5 of 10
(50%) patients in the Xelox-alone group, with the most
common being diarrhoea and vomiting (Table 5). Grade
IIIeIV diarrhoea was deemed related to Xelox treat-
ment for both patients in the Xelox þ AZD8931 group
and related to AZD8931 for one of them. In the Xelox
only group, grade IIIeIV diarrhoea was related to the
Xelox treatment for one patient. There were 13 SAEs
during the neoadjuvant treatment period, with 43% (3/7)
reported among the Xelox þ AZD8931 group deemed
related to AZD8931. The most common SAE wasdiarrhoea, of which there were four occurrences (Table
6).
All 11 patients experienced an AE during AZD8931
postoperative maintenance. In total, there were 33 AEs
(n Z 19, 58% related to AZD8931), with the most
common grade IeIV AE being skin rash, experienced by
four patients (36%) on AZD8931 maintenance (related
to AZD8931 in three patients). There were two grade III
AEs: metastases to central nervous system and arthritis,
both considered not to be related to AZD8931. OneUnknown 0 1 3 1 0 1
Table 4
Number (%) of patients with grade IIIeIV AEs of each type during the escalation phasea.
n (%) 20 mg Continuous
(n Z 6)
20 mg 14ON 7OFF
(n Z 7)
20 mg 4ON 3OFF
(n Z 7)
40 mg 4ON 3OFF
(n Z 4)
Total
(n Z 24)
Diarrhoea 3 (50%) 1 (14%) 1 (14%) 2 (50%) 7 (29%)
Vomiting e 3 (43%) 1 (14%) e 4 (17%)
Nausea 1 (17%) e 1 (14%) e 2 (8%)
Gastrointestinal
haemorrhage
2 (33%) e e e 2 (8%)
Neutropenia e 2 (29%) e e 2 (8%)
Pyrexia e 1 (14%) e 1 (25%) 2 (8%)
Fatigue 2 (33%) e e e 2 (8%)
Dehydration 1 (17%) e 1 (14%) e 2 (8%)
Pulmonary embolism 1 (17%) 1 (14%) e e 2 (8%)
a Only AEs occurring in 5% of patients are reported in this table.
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metastasis) was considered related to the underlying
disease.
Two SUSARs were reported during the expansion
phase: thoracotomy wound dehiscence
(Xelox þ AZD893) and hypophosphataemia (Xelox-
only), both of which were grade IV.3.4. Maximum tolerated dose
In total, 22 of 24 patients were evaluable for the dose
escalation analysis. Four DLTs were observed amongst
22 patients: (1) failure to deliver 100% of the planned
dose of Xelox because of grade III fatigue attributable
to AZD8931 with or without Xelox; (2) failure to deliverFig. 3. Percentage of patients with AEs in each system orga100% of the planned dose of Xelox because of grade III
diarrhoea and vomiting attributable to AZD8931 with
or without Xelox; (3) failure to deliver 100% of the
planned dose of Xelox because of grade III vomiting
attributable to AZD8931 with or without Xelox; (4)
grade III rash which persisted for at least 5 days despite
optimal treatment. No DLTs were observed in the 20-
mg bd 14d on/3d off schedule, which was declared as the
RP2D.3.5. Survival and resection rates
In the dose expansion phase, median follow-up was 26.8
months. Ten patients (33%) progressed or died during
the course of the expansion phase: 9 (45%) patients inn during neoadjuvant treatment in the expansion phase.
Table 5
Number (%) of patients with grade III-IV adverse events (AE) of each
type during neoadjuvant treatment for the randomised expansion
phase.
AE term Xelox þ AZD8931
(n Z 20)
XELOX
(n Z 10)
Diarrhoeaa 2 (10%) 2 (20%)
Vomitinga,b 1 (5%) 1 (10%)
Hypophosphataemia e 1 (10%)
Liver function test abnormalb e 1 (10%)
Pulmonary embolisma 1 (5%) 1 (10%)
Sepsis e 1 (5%)
a One patient in the AZD893 þ XELOX group had three grade
IIIeIV AEs: diarrhoea, vomiting and pulmonary embolism.
b One patient in the XELOX-alone group had two grade IIIeIV
AEs: vomiting and liver test function abnormal.
A. Thomas et al. / European Journal of Cancer 124 (2020) 131e141138the Xelox þ AZD8931 group and 1 (10%) in the Xelox-
alone group. Median PFS could not be estimated in
either groups (Fig. 4A). The lower 90% confidence limit
for median PFS in the Xelox þ AZD8931 group was
estimated as 9.1 months. PFS at six months was 85%
(90% CI: 66%, 94%) in the Xelox þ AZD8931 group
and 100% in the Xelox-alone group.
Eight deaths (all disease-related) occurred during
the expansion phase; 7 (35%) deaths in the
Xelox þ AZD8931 group and 1 (10%) in the Xelox-
alone group. OS at 12 months was 87% (90% CI: 72%,
94%) overall: 80% (90% CI: 60%, 91%) in the
Xelox þ AZD8931 group and 100% in the Xelox alone
group (Fig. 4B). OS at 24 months was 72% (90% CI:
56%, 84%) overall: 64% (90% CI: 43%, 79%) in the
Xelox þ AZD8931 group and 90% (90% CI: 58%, 98%)
in the Xelox-alone group. Median OS time could not
be estimated for either group. The lower 90% confi-
dence limit for median OS time in the
Xelox þ AZD8931 group was estimated as 17.9
months.
The proportion of patients achieving R0 resection at
surgery was 45% (n Z 9) in the Xelox þ AZD8931Table 6
Serious adverse events (SAEs) that occurred during neoadjuvant treatmen
Treatment group SAE Grade
Xelox þ AZD8931 Diarrhoea II
Xelox þ AZD8931 Diarrhoea 111
Xelox þ AZD8931 Diarrhoea 111
Xelox þ AZD8931 Haematuria I
Xelox þ AZD8931 Haematuria I
Xelox þ AZD8931 Pain I
Xelox þ AZD8931 Vomiting III
Xelox Diarrhoea III
Xelox Dyspepsia II
Xelox Hypophosphatemiaa IV
Xelox Out of range LFTs III
Xelox Sepsis III
Xelox Vomiting III
LFT, liver function test; NA, not applicable.
a SUSAR.group and 90% (n Z 9) in the Xelox-alone group
(P Z 0.024). All patients who underwent surgery ach-
ieved either R0 or R1 resection.
4. Discussion
Defining new treatment options in OGC is critical for
improving outcomes. Approximately 30% of patients
with OGC have disease characterised by HER2 ampli-
fication [21] and benefit from treatment with the anti-
HER2 monoclonal antibody, trastuzumab. However,
benefit may also be realised in HER2-low or HER2-
negative tumours by targeting the wider EGFR family.
ErbB3 expression, for example, has been increasingly
characterised in oesophageal cancers [22,23] and is
associated with poor prognosis [24]. Furthermore, erbB3
plays a central role in signal transduction via the phos-
phatidylinositol-3-kinase pathway, activating both
EGFR and HER2 to further deregulate pro-
proliferative signalling networks. AZD8931 is an equi-
potent reversible inhibitor of EGFR, erbB2, and erbB3
[25] which may therefore offer added therapeutic benefit
across a wider range of OGC molecular subtypes.
The primary end-point for DEBIOC was to deter-
mine the MTD for AZD8931 in combination with Xelox
chemotherapy in patients with OGC. The four DLTs
observed in the escalation phase included the AEs
diarrhoea and vomiting, reflecting the most commonly
reported AEs across all dose levels. A dose finding study
of AZD8931 in patients with advanced solid tumours by
Tjulandin et al. [26], gave bi-daily single-agent dosing
from 40 to 300 mg. Here, diarrhoea was also the most
common AE across all doses and contributed to two
DLTs in the 300-mg cohort. However, in FOCUS-4, a
molecularly stratified randomised trial in patients with
colorectal cancer, a 40 mge20 mg dose reduction in
AZD8931 was mandated primarily because of skin rash
in 20% of patients [27]. The multi-institutional,t for the expansion phase, by treatment group.
Related to
AZD8931 Capecitabine Oxaliplatin
Probably Probably Probably
Possibly Possibly Probably not
Possibly Definitely Possibly
Probably not Definitely not Definitely not
Probably not Definitely not Definitely not
Probably not Probably not Probably not
Definitely not Probably Possibly
NA Definitely Possibly
NA Possibly Probably
NA Probably not Probably
NA Probably Possibly
NA Definitely Definitely
NA Probably Possibly
10 10 10 10 9 9 8 6 6 5 2 0 0Xelox alone
20 18 17 15 13 13 12 8 7 5 3 0 0Xelox+AZD8931
Number at risk
0 3 6 9 12 15 18 21 24 27 30 33 36
Time from randomisation (months)
AZD8931+Xelox
Xelox alone
Pr
og
re
ss
io
n-
fr
ee
Su
rv
iv
al
(%
)
0
25
50
75
100A
10 10 10 10 10 9 8 6 6 5 2 0 0Xelox alone
20 20 18 16 16 15 14 10 8 5 3 0 0Xelox+AZD8931
Number at risk
0 3 6 9 12 15 18 21 24 27 30 33 36
Time from randomisation (months)
AZD8931+Xelox
Xelox alone
0
25
50
75
100
O
ve
ra
ll
Su
rv
iv
al
(%
)
B
Fig. 4. Kaplan-Meier plots showing progression-free survival as per
RECIST 1.1 (A) and overall survival (B) for participants receiving
AZD8931 þ Xelox vs Xelox alone in the expansion phase.
A. Thomas et al. / European Journal of Cancer 124 (2020) 131e141 139neoadjuvant therapy (MINT) study assessed the com-
bination of AZD8931 with anastrozole in breast cancer
patients, revealing an increased incidence of diarrhoea,
rash, and acneform dermatitis compared with placebo
[28]. In addition, discontinuation of anastrozole was
reported at greater rates for those receiving AZD8931
than placebo. In contrast, during the expansion phase of
DEBIOC, diarrhoea was reported at similar rates for
both arms whereas overall grade IIIeIV AEs were re-
ported in 10% patients in the Xelox þ AZD8931 group
compared with 50% patients receiving Xelox alone,
suggesting that this combination is both safe and toler-
able. DEBIOC is also the first study to consider
AZD8931 in long-term postsurgical maintenance ther-
apy, during which time 58% patients experienced
AZD8931-related AEs, the most common being skinrash. Although skin rash is a common grade IIIeIV
toxicity typically occurring in 10e20% of patients
receiving tyrosine kinase inhibitors [29], no events of this
nature  grade III were observed with AZD8931 in the
expansion phase.
The discordance between the diagnostic biopsy and
resection specimens for both HER2 and EGFR status,
demonstrates potential heterogeneity of expression in
these cancers or indeed a neoadjuvant treatment effect.
There is clear evidence to support molecular stratifica-
tion to identify those patients who will gain clinical
benefit from being exposed to targeted agents [13,30].
Eliminating this discordance is essential if we are going
to accurately stratify patients to receive targeted agents.
Neoadjuvant chemotherapy offers significant survival
benefit (equating to approximately 7% at 2 years) in OGC
compared with surgery alone [31,32]. Previous studies
specifically assessing neoadjuvant Xelox in oesophageal
cancer estimated a 2-year OS to be 42% and PFS to be
32.5% [33]. In the UKMRCOE05 study, OS at two years
was approximately 50% (taken from their Kaplan-Meier
curve [10]. In DEBIOC, OS at two years was 72% (90%
CI: 56%, 84%). InDEBIOC,median PFS in both armswas
not established because of the small proportion of events
per group. R0 resection rates of 90% in the Xelox-only
group were significantly better than for the AZD8931
arm but were alsomuch higher thanwould be expected for
Xelox alone, with R0 resection following neoadjuvant
chemotherapy typically ranging from approximately
59%e82% [5,10,34,35]. The small size of this study is likely
a major contributing factor to these disparities.5. Conclusions
The RP2D of the equipotent inhibitor of EGFR, erbB2,
and erbB3, AZD8931, in combination with standard-of-
care neoadjuvant Xelox chemotherapy in resectable
patients with OGC is 20-mg bd (4 days on/3 off every
week). Although the sample size was too small to draw
conclusions regarding efficacy, this study shows that
expansion of triplet neoadjuvant therapy to include a
pan-erbB inhibitor, where specific HER2-targeting
therapies may not be appropriate, appears both safe and
tolerable.Funding
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